Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NSRX

Nasus Pharma Ltd

Aug 26 • 04:00PM ET

8.03

Dollar change +0.04
Percentage change 0.50	%

Healthcare • Drug Manufacturers - General • Israel • AMEX

Index	-	P/E	-	EPS (ttm)	-0.17	Insider Own	6.38%	Shs Outstand	9.01M	Perf Week	-7.59%
Market Cap	72.35M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	8.43M	Perf Month	-
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	-2.67%
Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W High	9.99 -19.62%	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	7.23 11.07%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	13.66% -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.96	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	-2.84%	Beta	-	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-2.84%	Rel Volume	0.74	Prev Close	7.99
Employees	1	LT Debt/Eq	-	Earnings	-	SMA200	-2.84%	Avg Volume	88.54K	Price	8.03
IPO	Aug 13, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	65,830	Change	0.50%

Aug-26-25 08:00AM	Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony (GlobeNewswire)
Aug-14-25 04:05PM	Nasus Pharma Announces Closing of Initial Public Offering (GlobeNewswire)
Aug-13-25 07:30AM	Nasus Pharma Announces Pricing of $10 Million Initial Public Offering (GlobeNewswire)

Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NSRX

Nasus Pharma Ltd

Upgrade your FINVIZ experience